Publications by authors named "R K Abhaichand"
Background: The role of percutaneous coronary interventions (PCI) in patients with diabetes mellitus and multi-vessel disease has been questioned by the results of the FREEDOM trial, which showed superiority of coronary artery bypass graft(CABG) over first generation drug-eluting stents (DES) including a reduction in mortality. In the light of safer and more efficacious stents and significantly better medical management, those results that date back to 2012 need to be revisited. TUXEDO-2 is a study designed to compare two contemporary stents in Indian diabetic patients with multi-vessel disease.
View Article and Find Full Text PDFPrognosis of PCI in the Older Adult Population: Outcomes From the Multicenter Prospective e-ULTIMASTER Registry.
J Soc Cardiovasc Angiogr Interv
August 2022
Background: Older adult patients undergoing percutaneous coronary intervention (PCI) are usually excluded from clinical trials. This study aimed to assess 1-year clinical outcomes in patients aged >80 years.
Methods: This all-comer registry included patients who underwent PCI using the Ultimaster stent.
Article Synopsis
- Nonadherence to antiplatelet therapy is prevalent among patients after percutaneous coronary intervention (PCI), even in clinical trials like the MASTER DAPT study aimed at high bleeding risk individuals.
- The study involved 4,579 patients randomized to receive either abbreviated or standard dual antiplatelet therapy, examining outcomes such as adverse clinical events and bleeding risks.
- Results showed that while adherence levels varied, the abbreviated treatment led to similar levels of adverse events but significantly reduced major bleeding compared to standard treatment.
Objective: The primary objective was to assess the performance of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer in an all comer population. The secondary objective was to detail differences in contemporary percutaneous coronary intervention (PCI) practice worldwide.
Methods: e-Ultimaster was an all-comer, prospective, global registry (NCT02188355) with independent event adjudication enrolling patients undergoing PCI with the study stent.
Aims: The aim of this study was to demonstrate the safety and efficacy of the next-generation balloon-expandable Myval transcatheter heart valve (THV) in an intermediate- or high-risk patient population with severe symptomatic native aortic stenosis.
Methods And Results: MyVal-1 was a first-in-human, prospective, multicentre, single-arm, open-label study. Between June 2017 and February 2018, a total of 30 patients were enrolled at 14 sites across India.